These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12180480)

  • 41. Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer.
    Dankoff JS
    J Urol; 1992 Dec; 148(6):1914. PubMed ID: 1433640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer.
    Rosenthal SA; Linstadt DE; Leibenhaut MH; Andras EJ; Brooks CP; Stickney DR; Chang GC; Wolkov HB; Gilbert RM
    Radiology; 1996 May; 199(2):451-5. PubMed ID: 8668793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hepatoxicity caused by flutamide increased by hypotensive situation?].
    Serrano Hernández N; García López F; Fedriani Gorria J
    An Med Interna; 1996 Nov; 13(11):552-4. PubMed ID: 9019217
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms.
    Pontiroli L; Sartori M; Pittau S; Morelli S; Boldorini R; Albano E
    Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):310-4. PubMed ID: 9759603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Caubet JF
    J Natl Cancer Inst; 1999 Feb; 91(4):381-2. PubMed ID: 10050874
    [No Abstract]   [Full Text] [Related]  

  • 49. Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites.
    Aizawa Y; Ikemoto I; Kishimoto K; Wada T; Yamazaki H; Ohishi Y; Kiyota H; Furuta N; Suzuki H; Ueda M
    Mol Cell Biochem; 2003 Oct; 252(1-2):149-56. PubMed ID: 14577588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular implications of the antiandrogen withdrawal syndrome.
    Moul JW; Srivastava S; McLeod DG
    Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
    [No Abstract]   [Full Text] [Related]  

  • 51. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
    Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
    JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anemia in patients on combined androgen block therapy for prostate cancer.
    Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
    Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
    Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
    Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 56. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.